- Home
- RMCO vs JSPR Comparison
RMCO vs JSPR Comparison
Compare RMCO & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RMCO | JSPR |
|---|---|---|
| Founded | 2021 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.7M | 43.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RMCO | JSPR |
|---|---|---|
| Price | $4.15 | $1.46 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 10 |
| Target Price | N/A | ★ $18.13 |
| AVG Volume (30 Days) | 43.6K | ★ 979.6K |
| Earning Date | 11-13-2025 | 02-26-2026 |
| Dividend Yield | ★ 0.22% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,798,352.00 | N/A |
| Revenue This Year | $531.90 | N/A |
| Revenue Next Year | $200.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 445.90 | N/A |
| 52 Week Low | $0.91 | $1.39 |
| 52 Week High | $5.00 | $7.19 |
Technical Indicators
Market Signals| Indicator | RMCO | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 60.31 | 39.59 |
| Support Level | $3.90 | $1.51 |
| Resistance Level | $4.61 | $1.66 |
| Average True Range (ATR) | 0.37 | 0.11 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 51.15 | 18.87 |
Price Performance
Historical ComparisonAbout RMCO Royalty Management Holding Corporation
Royalty Management Holding Corp formed to invest or purchase assets that have current or near-term income to provide the company with accretive cash flow from which it can reinvest in new assets or expand cash flow from existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.